Latest News and Press Releases
Want to stay updated on the latest news?
-
ICT’s lead “armored” CAR-T program, ICTCAR014, demonstrated responses in two patients treated for refractory diffuse large B-cell lymphoma (DLBCL) in an investigator-sponsored clinical trial in China;...
-
中國上海和馬里蘭州羅克維爾, April 10, 2019 (GLOBE NEWSWIRE) -- 斯丹赛生物技术有限公司 (Innovative Cellu lar Therapeutics, ICT）是一間生物技術公司，主力開發治療癌症的細胞免疫療法。該公司在今天宣布與美國食品和藥物管理局（FDA）的臨床試驗審查前會議﹙研究性新藥﹚已圓滿結束。在會議上，FDA 就 ICT...
-
中国上海及美国马里兰州罗克维尔, April 10, 2019 (GLOBE NEWSWIRE) -- 斯丹赛生物技术有限公司（Innovative Cellular...
-
SHANGHAI, China and ROCKVILLE, Md., April 09, 2019 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a biotechnology company developing cellular immunotherapies for the treatment of...
-
ROCKVILLE, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a biotechnology company developing cellular immunotherapies for the treatment of cancer, today announced it...
-
ROCKVILLE, Md., March 06, 2019 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a biotechnology company developing cellular immunotherapies for the treatment of cancer, today announced...